Results 81 to 90 of about 234,795 (273)
JEADV Clinical Practice, EarlyView.ABSTRACT Mycosis fungoides is a misnomer that means ‘mushroom‐like fungal disease’, but it is, in fact, the most common form of cutaneous T‐cell lymphoma. The diagnosis of mycosis fungoides is often delayed due to non‐specific symptoms and cutaneous signs that mimic other common benign inflammatory dermatoses.
Ji Fung Yong +5 more
wiley +1 more source
Emerging targeted therapies for plaque psoriasis – impact of ixekizumab
, 2017 Tiana Kazemi,1 Benjamin Farahnik,2 John Koo,3 Kourosh Beroukhim1 1University of California – Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 2University of Vermont College of Medicine, Burlington, VT, 3University of California –
Koo J, Kazemi T, Beroukhim K, Farahnik B
core
JEADV Clinical Practice, EarlyView.ABSTRACT Background Subcorneal pustular dermatosis (SPD), or Sneddon–Wilkinson disease, is a rare, relapsing pustular skin condition of unknown cause, characterised by subcorneal pustules. Objectives To summarise the demographic, clinical, histopathological, management and disease course of SPD.
Mason H. Crossman +5 more
wiley +1 more source
Clinical, Cosmetic and Investigational DermatologyFan Jiang, Lingyi Lu, Sihan Wang, Feng Yuan, Lu Cao, Suling Xu,* Bingjiang Lin* Department of Dermatology, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang; National Clinical Medical Research Center for Skin and Immune ...
Jiang F +6 more
doaj
Treating pediatric plaque psoriasis: challenges and solutions
, 2016 Jayakar Thomas,1 Kumar Parimalam,2 1Department of Dermatology, Sree Balaji Medical College, Bharath University, Chennai, Tamil Nadu, India; 2Department of Dermatology, Villupuram Medical College, Villupuram, Tamil Nadu, India Abstract: Psoriasis is a T ...
Parimalam K, Thomas J
core
Real‐World Effectiveness of Tildrakizumab in Biologic‐Naive Plaque Psoriasis: A Case Series
JEADV Clinical Practice, EarlyView.ABSTRACT Background Tildrakizumab is a selective interleukin‐23 p19 inhibitor approved for moderate‐to‐severe plaque psoriasis. Real‐world data, specifically in biologic‐naive patients, remains limited. Objectives To evaluate the real‐world effectiveness and safety of tildrakizumab 100 mg in biologic‐naive patients with moderate‐to‐severe plaque ...
Davindra Singh +2 more
wiley +1 more source
FLI1 Induces Plaque Psoriasis and Its Inhibition Attenuates Disease Progression [PDF]
Maoting Hu,1,2 Kunlin Yu,1,2 Chunlin Wang,1,2 Wuling Liu,1,2 Anling Hu,1,2 Yi Kuang,1,2 Babu Gajendran,3 Eldad Zacksenhaus,4 Giulio Sartori,5 Francesco Bertoni,5,6 Xiao Xiao,1,2 Yaacov Ben-David1,2 1State Key Laboratory of Discovery and Utilization of ...
Sartori G +11 more
core
JEADV Clinical Practice, EarlyView.Skin samples of Hailey‐Hailey and Darier diseases were analyzed for inflammatory and barrier markers using indirect immunofluorescence and transcriptomic techniques. A mixed Th2/Th17 inflammatory pattern and altered expression of barrier markers were observed.
Ella Glodjajic +10 more
wiley +1 more source
Trials, 2019 Background Psoriasis is a chronic, immune-mediated disorder with chronic plaque psoriasis being the primary manifestation during the remission stage. Patients often have a slow course and long history of the disease. The refractory type of psoriasis is a
Zhaoxia Chen +14 more
doaj +1 more source
Novel topical therapy for mild-to-moderate plaque psoriasis: focus on calcitriol
, 2009 Lutz KowalzickDepartment of Dermatology and Allergology, HELIOS Vogtland-Klinikum Plauen GmbH Plauen, GermanyAbstract: The benefits of vitamin D derivatives for the treatment of chronic plaque psoriasis are well documented.
Lutz Kowalzick
core